BACKGROUND: A subset of triple-negative breast cancer (TNBC) has been reported to express androgen receptor (AR); however, the clinical significance of AR expression in TNBC is unclear. METHODS: We examined immunohistochemical expression of AR in a large cohort of TNBC cases and correlated its expression with clinicopathologic features and clinical outcome. RESULTS: AR expression was found in 17.7% (87/492) of TNBCs. Positive expression of AR showed significant correlation with older age (p < 0.001), apocrine histology (p = 0.001), and lower histologic grade (p < 0.001). AR was a poor prognostic marker for overall survival (OS) in univariate (p = 0.026) and multivariate (p = 0.008) analyses. In the lymph node-negative (n = 316) subgroup, AR expression was a significant predictor of worse OS and disease-free survival (DFS) in both univariate (p = 0.028 and 0.011) and multivariate (p = 0.024 and 0.01, respectively) analyses. AR expression also was a prognostic factor in pT1 subgroup (OS, p = 0.007; DFS, p = 0.01); however, its prognostic value was not observed in TNBC patients with lymph node metastasis or tumor size larger than pT1. CONCLUSIONS: AR-expressing TNBCs represent a distinct breast cancer subgroup with adverse clinical outcome and AR blockade could be a potential endocrine therapy for these TNBC patients. Evaluation of AR status may provide additional information on prognosis and treatment in patients with TNBC.
BACKGROUND: A subset of triple-negative breast cancer (TNBC) has been reported to express androgen receptor (AR); however, the clinical significance of AR expression in TNBC is unclear. METHODS: We examined immunohistochemical expression of AR in a large cohort of TNBC cases and correlated its expression with clinicopathologic features and clinical outcome. RESULTS:AR expression was found in 17.7% (87/492) of TNBCs. Positive expression of AR showed significant correlation with older age (p < 0.001), apocrine histology (p = 0.001), and lower histologic grade (p < 0.001). AR was a poor prognostic marker for overall survival (OS) in univariate (p = 0.026) and multivariate (p = 0.008) analyses. In the lymph node-negative (n = 316) subgroup, AR expression was a significant predictor of worse OS and disease-free survival (DFS) in both univariate (p = 0.028 and 0.011) and multivariate (p = 0.024 and 0.01, respectively) analyses. AR expression also was a prognostic factor in pT1 subgroup (OS, p = 0.007; DFS, p = 0.01); however, its prognostic value was not observed in TNBC patients with lymph node metastasis or tumor size larger than pT1. CONCLUSIONS:AR-expressing TNBCs represent a distinct breast cancer subgroup with adverse clinical outcome and AR blockade could be a potential endocrine therapy for these TNBC patients. Evaluation of AR status may provide additional information on prognosis and treatment in patients with TNBC.
Authors: Tracy Proverbs-Singh; Jarett L Feldman; Michael J Morris; Karen A Autio; Tiffany A Traina Journal: Endocr Relat Cancer Date: 2015-02-26 Impact factor: 5.678
Authors: Daniel L J Thorek; Philip A Watson; Sang-Gyu Lee; Anson T Ku; Stylianos Bournazos; Katharina Braun; Kwanghee Kim; Kjell Sjöström; Michael G Doran; Urpo Lamminmäki; Elmer Santos; Darren Veach; Mesruh Turkekul; Emily Casey; Jason S Lewis; Diane S Abou; Marise R H van Voss; Peter T Scardino; Sven-Erik Strand; Mary L Alpaugh; Howard I Scher; Hans Lilja; Steven M Larson; David Ulmert Journal: Sci Transl Med Date: 2016-11-30 Impact factor: 17.956
Authors: Jane Date C Hon; Baljit Singh; Aysegul Sahin; Gang Du; Jinhua Wang; Vincent Y Wang; Fang-Ming Deng; David Y Zhang; Marie E Monaco; Peng Lee Journal: Am J Cancer Res Date: 2016-09-01 Impact factor: 6.166
Authors: Rosalind P Candelaria; Beatriz E Adrada; Wei Wei; Alastair M Thompson; Lumarie Santiago; Deanna L Lane; Monica L Huang; Elsa M Arribas; Gaiane M Rauch; W Fraser Symmans; Michael Z Gilcrease; Lei Huo; Bora Lim; Naoto T Ueno; Stacy L Moulder; Wei Tse Yang Journal: Eur J Radiol Date: 2019-03-21 Impact factor: 3.528